Tryptamine Therapeutics (AU:TYP) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics Limited, a biotech firm specializing in psychedelic-assisted therapies, has requested a trading halt on the ASX. The halt is in anticipation of a major update concerning their oral psilocybin study, with the halt to remain until an announcement is made or trading resumes on August 12, 2024.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.